Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00658697 · ClinicalTrials.gov registry record · Phase 2
Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
NCT00658697 is a Phase 2 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 42 participants.
The verdict
NCT00658697, a Phase 2 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
Study Summary
In this research study, we aim to evaluate the feasibility, toxicity and efficacy of early multimodality systemic therapy (a combination of docetaxe, bevacizumab, and androgen deprivation therapy(ADT) in men with biochemical recurrence (BCR) or who have a rising Prostate Specific Antigen (PSA) after treatment of their prostate cancer with surgery or radiation)
Interventions
- DRUG Bevacizumab
- DRUG Docetaxel
- DRUG ADT
- DRUG Bicalutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2008-06 |
| Est. Completion | 2015-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00658697
The ClinicalTrials.gov registry entry for NCT00658697 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Bevacizumab is the first listed.
NCT00658697 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00658697 about?
NCT00658697 is a clinical study titled "Docetaxel, Bevacizumab and Androgen Deprivation Therapy After Definitive Local Therapy for Prostate Cancer". In this research study, we aim to evaluate the feasibility, toxicity and efficacy of early multimodality systemic therapy (a combination of docetaxe, bevacizumab, and androgen deprivation therapy(ADT) in men with biochemical recurrence (BCR) or who have a rising Prostate Specific Antigen (PSA) after...
What is the current status of trial NCT00658697?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2008-06. Estimated completion is 2015-06.
What interventions are being tested in trial NCT00658697?
The interventions under investigation include: Bevacizumab (DRUG), Docetaxel (DRUG), ADT (DRUG), Bicalutamide (DRUG).
Who is sponsoring clinical trial NCT00658697?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.